Clinical Trial Update: Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating three doses of NewGam for chronic inflammatory demyelinating polyradiculoneuropathy has been terminated. The update concerns safety a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyradiculoneuropathy

Drugs mentioned

• NewGam (intravenous immunoglobulin)

Snippet

Sponsor: Octapharma | Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 2, Phase 3 | Status: TERMINATED